Roche signed a collaboration with Defand Therapeutics to discover and develop molecular glue medicines for cancer and immune-driven diseases. The reporting indicates terms could reach close to $1 billion based on preclinical, clinical, and regulatory milestones, reinforcing that large pharma is increasingly shifting from licensing to joint discovery in China’s early-stage biopharma ecosystem.